News Datroway filed for TNBC in EU after data delay Daiichi Sankyo and AstraZeneca have filed their first marketing application for TROP2-targeting Datroway in triple-negative breast cancer.
News MSD claims two national priority vouchers; report The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD drug candidates.
News As year-end nears, pharma groups plump up their pipelines Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.
News Padcev/Keytruda scores again in early bladder cancer Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.
News Enhertu moves into frontline breast cancer treatment Daiichi Sankyo and AstraZeneca's Enhertu has become the first new first-line option in the US for HER2-positive breast cancer in more than a decade.
News J&J claims FDA's latest national priority voucher The FDA has awarded its latest national priority voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma.
Digital Trustworthy and novel AI in clinical trial planning, with Kr... Norstella's Kris Kaneta discusses why patient-level data is pharma's most important asset, as well as expanding the efficacy of AI for clinical trials
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
